ARTICLE | Company News
Domain Therapeutics S.A. (Strasbourg, France) said it partnered with Merck KGaA (Xetra:MRK) to develop adenosine receptor inhibitors to treat cancer. Domain is eligible to receive an undisclosed upfront payment and milestones totaling EUR 240 million ($257.5 million), plus royalties.
Merck will fund development of the inhibitors and will hold worldwide rights in all indications to candidates in the collaboration. Domain declined to give a specific timeline for preclinical and clinical development...